Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

770 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Early assessment of KRAS mutation in cfDNA correlates with risk of progression and death in advanced non-small-cell lung cancer.
Zulato E, Attili I, Pavan A, Nardo G, Del Bianco P, Boscolo Bragadin A, Verza M, Pasqualini L, Pasello G, Fassan M, Calabrese F, Guarneri V, Amadori A, Conte P, Indraccolo S, Bonanno L. Zulato E, et al. Among authors: conte p. Br J Cancer. 2020 Jul;123(1):81-91. doi: 10.1038/s41416-020-0833-7. Epub 2020 May 7. Br J Cancer. 2020. PMID: 32376889 Free PMC article.
Mitomycin-ifosfamide-cisplatinum (MIP) vs MIP-interferon vs cisplatinum-carboplatin in metastatic non-small-cell lung cancer: a FONICAP randomised phase II study. Italian Lung Cancer Task Force.
Ardizzoni A, Addamo GF, Baldini E, Borghini U, Portalone L, De Marinis F, Lionetto R, Conte PF, Bruzzi P, Pennucci MC, et al. Ardizzoni A, et al. Among authors: conte pf. Br J Cancer. 1995 Jan;71(1):115-9. doi: 10.1038/bjc.1995.23. Br J Cancer. 1995. PMID: 7529522 Free PMC article. Clinical Trial.
Weekly docetaxel/paclitaxel in pretreated metastatic breast cancer.
Gennari A, Guarneri V, Landucci E, Orlandini C, Rondini M, Salvadori B, Ricci S, Conte PF. Gennari A, et al. Clin Breast Cancer. 2002 Dec;3(5):346-52. doi: 10.3816/CBC.2002.n.038. Clin Breast Cancer. 2002. PMID: 12533265 Clinical Trial.
Randomised controlled trial comparing single agent paclitaxel vs epidoxorubicin plus paclitaxel in patients with advanced ovarian cancer in early progression after platinum-based chemotherapy: an Italian Collaborative Study from the Mario Negri Institute, Milan, G.O.N.O. (Gruppo Oncologico Nord Ovest) group and I.O.R. (Istituto Oncologico Romagnolo) group.
Buda A, Floriani I, Rossi R, Colombo N, Torri V, Conte PF, Fossati R, Ravaioli A, Mangioni C. Buda A, et al. Among authors: conte pf. Br J Cancer. 2004 Jun 1;90(11):2112-7. doi: 10.1038/sj.bjc.6601787. Br J Cancer. 2004. PMID: 15150623 Free PMC article. Clinical Trial.
Concomitant versus sequential administration of epirubicin and paclitaxel as first-line therapy in metastatic breast carcinoma: results for the Gruppo Oncologico Nord Ovest randomized trial.
Conte PF, Guarneri V, Bruzzi P, Prochilo T, Salvadori B, Bolognesi A, Aldrighetti D, Venturini M, Rosso R, Mammoliti S, Carnino F, Giannessi P, Costantini M, Moyano A, Baldini E; Gruppo Oncologico Nord Ovest. Conte PF, et al. Cancer. 2004 Aug 15;101(4):704-12. doi: 10.1002/cncr.20400. Cancer. 2004. PMID: 15305399 Free article. Clinical Trial.
770 results